Biotech Investor Sees Covid-19 Drug Shaking Off Tarnished Past

Biotech investor Dale Chappell was looking to start Humanigen Inc. with a clean slate when his hedge fund assumed control in 2016, but things took longer than expected.

The stock has swelled over 500% this year after positive early results from an experimental treatment for a potentially lethal side-effect of Covid-19. The shares have been volatile since July when it reached a more-than four-year high, though results expected this quarter from a late-stage study may be the ticket to keep Humanigen on track after a roller coaster ride.

Dale Chappell

Source: Humanigen Inc.

Chappell, who has a medical degree from Dartmouth College and served ...